In conclusion, intestinal insulin signaling plays a protective role against the development of nonalcoholic steatohepatitis and hepatocellular carcinoma associated with diabetes in mice, and treatments leading to the preservation of insulin action in the gut of patients with diabetes could be useful for prevention of NASH and HCC. The gene discussed is INS; the disease is hepatocellular carcinoma.